Kirby Institute

30_kirby_supplied.jpg

The Kirby Institute's new research collaboration with Myanmar's University of Medicine 2 will build research capacity in infectious diseases in the country, which faces considerable health challenges.

28_hepatitis_c.jpg

More Australians have been treated for hepatitis C in the past 12 months than the last decade combined, following the listing of a new generation therapy on the Pharmaceutical Benefits Scheme.

6_profmichellehaber_and_team.jpg

Clinical trials for childhood cancer and studies into pain medicine addiction and teenagers living with OCD are among UNSW projects to receive backing from the NHMRC.

irish_premier_2.jpg

For their work in surface chemistry, HIV/AIDS and memory disruption in dementia, three UNSW researchers have won four prestigious Royal Society of NSW Awards for 2016.

5_ecigs.jpg

A UNSW research trial to examine if e-cigarettes can help smokers quit and a world-first treatment for teenagers with PTSD and substance abuse are among projects to receive major backing in the latest NHMRC funding round.

Hiv_ribbons.jpg

On World AIDS Day, UNSW’s Kirby Institute has been awarded a $12 million grant to conduct a clinical trial to improve treatment options for people with HIV who have failed first-line antiretroviral therapy.

21 David Cooper 0 0

As it marks its 30th anniversary, the groundbreaking HIV research of UNSW’s Kirby Institute and its pioneering leader David Cooper has been acknowledged by the prestigious medical journal, The Lancet.

14_chlamydia_test.jpg

New HIV notifications in the non-Indigenous population have stabilised while rates among Aboriginal and Torres Strait Islander men have doubled over the past five years, according to new research.  

29_hepatitis_2.jpg

Australia is on track to cure more people of hepatitis C in 2016 alone than in the past 20 years, according to a new report from UNSW's Kirby Institute.

28_hepatitis_c.jpg

New hepatitis C treatments are expensive but Greg Dore and Marianne Martinello argue that facilitating global access to safe, direct-acting antivirals will herald a revolution. 

Pages